Back to Journals » Clinical Interventions in Aging » Volume 11

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration

Authors Michalska-MaĊ‚ecka K, Kabiesz A, Kimsa MW, StrzaĊ‚ka-Mrozik B, FormiĊ„ska-KapuĊ›cik M, Nita M, Mazurek U

Received 5 August 2015

Accepted for publication 14 October 2015

Published 24 March 2016 Volume 2016:11 Pages 357—365

DOI https://doi.org/10.2147/CIA.S93820

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Supriya Swarnkar

Peer reviewer comments 3

Editor who approved publication: Dr Richard Walker

Katarzyna Michalska-MaĊ‚ecka,1,2 Adam Kabiesz,2 Malgorzata W Kimsa,3 Barbara StrzaĊ‚ka-Mrozik,3 Maria FormiĊ„ska-KapuĊ›cik,2,4 Malgorzata Nita,5 Urszula Mazurek3

1Clinical Department of Ophthalmology, Medical University of Silesia, Katowice, Poland; 2University Center for Ophthalmology and Oncology, Independent Public Clinical Hospital, Medical University of Silesia, Katowice, Poland; 3Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Katowice, Poland; 4Clinical Department of Children Ophthalmology, Medical University of Silesia, Katowice, Poland; 5Domestic and Specialized Medicine Centre “Dilmed”, Katowice, Poland

Abstract: The purpose of this study was to evaluate the systemic effects of intravitreal ranibizumab (Lucentis) treatment in patients with neovascular age-related macular degeneration (AMD). The impact of intravitreal ranibizumab injections on central retinal thickness (CRT) of treated and contralateral untreated eyes, and differences in gene expression patterns in the peripheral blood mononuclear cells were analyzed. The study included 29 patients aged 50 years old and over with diagnosed neovascular AMD. The treatment was defined as 0.5 mg of ranibizumab injected intravitreally in the form of one injection every month during the period of 3 months. CRT was measured by optical coherence tomography. The gene expression profile was assigned using oligonucleotide microarrays of Affymetrix HG-U133A. Studies have shown that there was a change of CRT between treated and untreated eyes, and there were differences in CRT at baseline and after 1, 2, and 3 months of ranibizumab treatment. Three months after intravitreal injection, mean CRT was reduced in the treated eyes from 331.97±123.62 to 254.31±58.75 µm, while mean CRT in the untreated fellow eyes reduced from 251.07±40.29 to 235.45±36.21 µm at the same time. Furthermore, the research has shown that among all transcripts, 3,097 expresses change after the ranibizumab treatment in relation to controls. Among these transcripts, 1,339 were up-regulated, whereas 1,758 were down-regulated. Our results show the potential systemic effects of anti-VEGF therapy for AMD. Moreover, our study indicated different gene expression in peripheral blood mononuclear cells before and after intravitreal ranibizumab treatment.

Keywords: ranibizumab, contralateral eye, central retinal thickness, oligonucleotide microarray

Corrigendum for this paper has been published.
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Does the use of acetylsalicylic acid have an influence on our vision?

Michalska-MaĊ‚ecka K, Regucka A, Ċšpiewak D, Sosnowska-PoĊ„ska M, Niewiem A

Clinical Interventions in Aging 2016, 11:1567-1574

Published Date: 3 November 2016

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration [Corrigendum]

Michalska-MaĊ‚ecka K, Kabiesz A, Kimsa MW, StrzaĊ‚ka-Mrozik B, FormiĊ„ska-KapuĊ›cik M, Nita M, Mazurek U

Clinical Interventions in Aging 2016, 11:775-776

Published Date: 14 June 2016

Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion

Michalska-MaĊ‚ecka K, Gaborek A, Nowak M, Halat T, PawĊ‚owska M, Ċšpiewak D

Clinical Interventions in Aging 2016, 11:699-705

Published Date: 23 May 2016

Readers of this article also read:

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012